Effect of piracetam on ECT-induced cognitive disturbances: A randomized, placebo-controlled, double-blind study

Journal of ECT

Volumn 18, Issue 3, 2002, Pages 130-137

  Tang, Wai Kwong ^a   Ungvari, Gabor S ^a   Leung, Henry Chi Ming ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Electroconvulsive therapy; Memory disturbances; Piracetam

Indexed keywords

ATROPINE; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; DIAZEPAM; ERGOTAMINE; INOSITOL; NALOXONE; NICARDIPINE; NIMODIPINE; PIRACETAM; SUXAMETHONIUM; THIOPENTAL; THYROID HORMONE; TRIHEXYPHENIDYL; VASOPRESSIN;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT FAILURE;

ADULT; DEPRESSION; DOUBLE-BLIND METHOD; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PIRACETAM; PLACEBOS; SCHIZOPHRENIA; TREATMENT FAILURE;

EID: 0036399892     PISSN: 10950680     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124509-200209000-00004     Document Type: Article

References (54)

1. Fink M. Indications for use of ECT. Psychopharmacol Bull 1994;30:269-75.
2. Cahill C, Frith C. Memory following electroconvulsive therapy. In: Baddeley AD, Wilson BA, Watts FN, eds. Handbook of Memory Disorders. Chichester, UK: John Wiley & Sons. 1995.
3. Khan A, Mirolo MH, Mirolo HA. Miller S. Can ECT-induced cognitive effects be altered pharmacologically? Progr Neuropsychopharmacol Biol Psychiatry 1993;17:861-73.
4. Shapira B, Tubi N, Lerer B. Balancing speed of response to ECT in major depression and adverse cognitive effects: role of treatment schedule. J ECT 2000;16:97-109.
5. Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry 2000;57:425-34.
6. Bailine SH, Rifkin A, Kayne E, et al. Comparison of bifrontal and bitemporal ECT for major depression. Am J Psychiatry 2000;157:121-3.
7. Sackeim HA, Devanand DP, Prudic J. Stimulus intensity, seizure threshold, and seizure duration: impact on the efficacy and safety of electroconvulsive therapy. Psychiatry Clin North Am 1991;14:803-43.
8. Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med 1993;328:839-46.
9. Suedfeld P, Ramirez CE, Remick RA. Memory effects of restricted environmental stimulation therapy (REST) and possible applications to ECT. Prog Neuropsychopharmacol Biol Psychiatry 1987:11:179-84.
10. Calev A, Fink M. Petrides G, et al. Caffeine pre-treatment enhances clinical efficacy and reduces cognitive effects of ECT. Convuls Ther 1993;9:95-100.
11. Mattis JA, Pettinati HM, Stephens S, Robin SE, Willis KW. A placebo-controlled evaluation of vasopressin for ECT-induced memory impairment. Biol Psychiatry 1990;27:289-303.
12. Tremont G, Stern RA. Use of thyroid hormone to diminish the cognitive side effects of psychiatric treatment. Psychol Bull 1997;33:273-80.
13. Zervas IM, Pehlivanidis AA, Papakostas YG, Markianos M, Papadimitriou GN, Stefanis CN. Effects of TRH administration orientation time and recall after ECT. J ECT 1998;14:236-40.
14. Ezzat DH, Ibraheem MM, Makhawy B. The effect of piracetam on ECT-induced memory disturbances. Brit J Psychiatry 1985;147:720-1.
15. Prudic J, Fitzsimons L. Nobler MS, Sackeim HA. Naloxone in the prevention of the adverse cognitive effects of ECT: a within-subject, placebo controlled study. Neuropsychopharmacology 1999;21:285-93.
16. Levine J, Pomerantz T, Stier S, Belmaker RH. Lack of effect of 6g inositol treatment on post-ECT cognitive function in humans. J Psychiatr Res 1995;29:487-9.
17. Cohen MR, Swartz CM. Absence of nimodipine premedication effect on memory after electroconvulsive therapy. Biol Psychiatry 1990:91:165-8.
18. Dubovsky SL, Buzan R, Thomas M, Kassner C, Cullum M. Nicardipine improves the antidepressant action of ECT butdoes not improve cognition. J ECT 2001;17:3-10.
19. Sachs GS, Gelenberg AJ, Bellinghausen B, Wojcik J, Falk WE, Farhadi AM, Jenike M. Ergoloid mesylates and ECT. J Clin Psychiary 1989;50:87-90.
20. Dimond SJ, Brouwers EY. Increase in the power of human memory in normal man through the use of drugs. Psychopharmacology 1976;49:307-9.
21. Mindus P, Cronholm B, Levander SE, Schalling D. Piracetam-induced improvement of mental performance. A controlled study on normally aging individuals. Acta Psychiatr Scand 1976;54:150-60.
22. Orgogozo JM. Piracetam in the treatment of acute stroke. Pharmacopsychiatry 1999;32(suppl 1):25-32.
23. Huber W. The role of piracetam in the treatment of acute and chronic aphasia. Pharmacopsychiatry 1999;32(suppl 1):38-43.
24. Israel L, Melac M, Milinkevitch D, Dubos G. Drug therapy and memory training programs: a double-blind randomized trial of general practice patients with age-associated memory impairment, Int Psychogeriatr 1994;6:155-69.
25. Genton P,. Guerrini R, Remy C. Piracetam in the treatment of cortical myoclonus. Pharmacopsychiatry 1999;32(suppl 1):49-53.
26. Oosterveld WJ. The effectiveness of piracetam in vertigo. Pharmacopsychiatry 1999;32(suppl 1):54-9.
27. Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, Amini-Nooshabadi H. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther 1999;24:369-74.
28. Koskiniemi M, Van Vleymen B, Hakamies L, Lamusuo S, Taalas J. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicenter, randomized, double-blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998;64:344-8.
29. Giurgea C. Piracetam: nootropic pharmacology of neurointegrative activity. Curr Dev Psychopharmacol 1976;3:223-73.
30. Miller WE, Eckert GP, Eckert A. Piracetam: novelty in a unique mode of action. Pharmacopsychiatry 1999;32(suppl 1):2-9.
31. Cohen S, Mueller W. Interaction of piracetam with several neurotransmitter receptors in central nervous system - relative specificity for 3H-glutamate sites. Arzneimittelforschung 350-2.
32. Peuvot J, Schnack A, Deleers M. Brasseur R. Piracetam-induced changes to membrane physical properties: a combined approach by 3 IP nuclear magnetic resonance and conformational analysis. Biochem Pharmacol 1995;50:1129-34.
33. Mueller WE, Koch S, Scheuer K. Rostock A, Bartsch R. Effects of piracetam on membrance fluidity in the aged mouse, rat and human brain. Biochem Pharmacol 1997;53:135-40,
34. Mueller WE. Haltmann H, Koch S, Scheuer K, Stoll S. Neuroiransmission in aging - therapeutic aspects. In: Racagni N. Brunelli N, Langer SZ, eds. Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction. Basel: Karger, 1994;166-73.
35. Mueller WE. Age-related quantitative and qualitative receptor changes and pharmacological reactivity. In: Racagni G, Mendlewicz J, eds. Treatment of Age-related Cognitive Dysfunction: Pharmacological and Clinical Evaluation. Basel: Karger, 1992;35-40.
36. Moriau M, Crasborn L, Lavenne-Pardonge E, von Frenckell R, Col-Debeys C. Platelet anticoagulant and theological properties of piracetam. Arzneimittelforschung 1993;43:110-8.
37. Bagadia VN. Gada MT, Mundra VK, et al. A double blind trial of piracetam (UCB 6215) and placebo in cases of post-ECT cognitive deficiency. J Postgrad Med 1980;26:116-20.
38. Royal College of Psychiatrists' Special Committee on ECT. The ECT Handbook. London: Royal College of Psychiatrists, 1995.
39. Bazire S. Psychotropic Drug Directory 2001/02. Salisbury, UK: Mark Allen Publishing Ltd, 2001.
40. Zheng Y. Zhao J, Philips M, et al. Validity and reliability of the Chinese Hamilton Depression Rating Scale. Br J Psychiatry 1988;152:660-4.
41. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
42. Guy W. ECDEU Assessmentt for Psychopharmacology. Washington. DC: HEW Public Health Service, 1976;534-7.
43. Endicott J, Spitzer R. Flies J. The Global Assessment Scale. Arch Gen Psychiatry 1976;33:766-71.
44. Woemer M, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 1988;24:112-7.
45. Andreasen NC. The scale for assessment of negative symptoms (SANS). Br J Psychiatry 1989;155(suppl 7):53-8.
46. Wechsler D. Wechsler Memory Scale-Revised. New York: Psychological Corporation, 1987.
47. Kopelman MD, Wilson BA. Baddeley AD. The autobiographic memory interview: a new assessment of autobiographic and personal semantic memory in amnesic patients. J Clin Exp Neuropsychol 1989;11:724-44.
48. Squire LR. Memory functions as affected by electroconvulsive therapy. Ann NY Acad Sci 1986;462:307-14.
49. Sobin C, Sackeim HA, Prudic J, Devanand, Moody B, McElhiney MC. Predictors of retrograde amnesia following ECT. Am J Psychiatry 1995;152:995-1001.
50. Lasarova MB, Mosharof AH, Petkov VD, Marlkovska VL, Petkov VV. Effect of piracetam and of standardized ginseng extract on the electroconvulsive shock-induced memory disturbances in "step-down" passive avoidance. Acta Physiol Pharmacol Bulgarica 1987;13:11-7.
51. Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Rev 1994;19:180-222.
52. Bhattacharya SK, Upadhyay SN, Jaiswal AK. Effect of piracetam on electroshock induced amnesia and decrease in brain acetylcholine in rats. Indian J Exp Biol 1993;31:822-4.
53. Sara S, David-Remacle M, Recovery from electroconvulsive shock-induced amnesia by exposure to the training environment: pharmacological enhancement by piracetam. Psychopharmacology 1974;36:59-66.
54. Borromei A, Carameli R, Conti M, Giancola LC, Guerra L. Nonpsychotic involutional inhibited depressions and psycho-organic deteriorations: treatment with Viloxazine and piracetam. Minerva Med 1989;80:475-82.